APA ציטוט

Yamamoto, N., Yamasaki, T., Takami, T., Uchida, K., Fujisawa, K., Matsumoto, T., . . . Sakaida, I. (2016). Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib. J Clin Biochem Nutr.

Citação norma Chicago

Yamamoto, Naoki, Takahiro Yamasaki, Taro Takami, Koichi Uchida, Koichi Fujisawa, Toshihiko Matsumoto, Issei Saeki, Shuji Terai, and Isao Sakaida. "Deferasirox, an Oral Iron Chelator, Prevents Hepatocarcinogenesis and Adverse Effects of Sorafenib." J Clin Biochem Nutr 2016.

ציטוט MLA

Yamamoto, Naoki, et al. "Deferasirox, an Oral Iron Chelator, Prevents Hepatocarcinogenesis and Adverse Effects of Sorafenib." J Clin Biochem Nutr 2016.